Cystatin C Assay Market

Cystatin C Assay Market by Product (Analyzers, Kits, Reagents), Method (ELISA, PETIA, IFA, CLIA, PENIA), Application (Diagnostics, Research), Sample Type (Blood, Urine), End User (Hospitals, Clinical Laboratories) & Region - Global Forecast to 2028

Report Code: MD 8813 Oct, 2023, by marketsandmarkets.com

Cystatin C Assay Market Size & Trends

The global cystatin C assay market in terms of revenue was estimated to be worth $377 million in 2023 and is poised to reach $540 million by 2028, growing at a CAGR of 7.5% from 2023 to 2028. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market. The growth of this market is majorly driven by the Increasing adoption of POC testing and presence of supportive government policies. However, raising awareness among healthcare providers about the benefits of cystatin C testing can be challenging.

Attractive Opportunities in the Cystatin C Assay Market

Cystatin C  Assay Market

To know about the assumptions considered for the study, Request for Free Sample Report

Cystatin C  Assay Market

Recession Impact on the Cystatin C Assay Market

During a recession, governments may face budget constraints and prioritize spending on essential services. This can lead to potential reductions in healthcare budgets, affecting reimbursement rates and procurement decisions for Cystatin C Assay products. Likewise, healthcare providers and institutions may face financial constraints and look for ways to reduce costs. This can lead to increased price sensitivity and potential pricing pressure on bone cement and glue products.

On the other hand, the conflict between Ukraine and Russia has the potential to create economic challenges and disrupt regional stability. It is possible that the conflict could contribute to a recession in the affected regions and have broader economic implications. The conflict can disrupt supply chains, leading to challenges in the procurement and distribution of bone cement and glue products. Transport routes may be affected, making it difficult to deliver products to healthcare facilities in conflict-affected areas. During economic downturns, healthcare budgets may be constrained, leading to reduced spending on diagnostic tests, including Cystatin C testing. Hospitals and healthcare facilities may prioritize essential services over non-urgent tests.

Cystatin C Assay Market Dynamics

Driver: Rising Prevalence of Kidney Diseases

Kidney diseases and disorders, including chronic kidney disease (CKD), are becoming more prevalent globally due to factors such as aging populations, hypertension, diabetes, and lifestyle changes. Cystatin C assays are valuable tools for accurately assessing kidney function and diagnosing kidney-related issues.

Chronic kidney disease (CKD) is becoming one of the world's most prevalent noncommunicable chronic diseases. The World Health Organization projects CKD to become the 5th most common chronic disease in 2040. (Source: PubMed 2023). Similarly, it is a progressive condition that affects >10% of the general population worldwide, amounting to >800 million individuals (Source: PubMed 2022). In addition, more than 850 million individuals have kidney diseases worldwide. (Source: AstraZeneca 2023).

As per the Pan American Health Organization 2021. In 2019, regionwide kidney diseases account for, 254,028 total deaths, 131,008 deaths in men, and 123,020 deaths in women. The age-standardized death rate due to kidney diseases was estimated at 15.6 deaths per 100,000 population. The countries with the highest age-standardized death rates due to kidney diseases are Nicaragua, El Salvador, Bolivia, Guatemala, Suriname, Honduras, and Ecuador.

More than 1 in 7 US adults–about 35.5 million people, or 14%–are estimated to have CKD (Source: CDC: 2023)

Likewise, Diabetes is a major risk factor for kidney diseases, particularly CKD. As the global incidence of diabetes continues to rise due to factors such as sedentary lifestyles and poor dietary habits, the prevalence of kidney diseases linked to diabetes also increases. For instance, as per the Institute of Health Metrics and Evaluation at the University of Washington found that in 2022, there were 529 million people in the world with diabetes. They projected that this will more than double to around 1.3 billion people by 2050. As

Similarly, rising government as well as private funding for kidney diseases drive the market. Government funding plays a crucial role in advancing research, diagnosis, and treatment of kidney diseases, and this funding can have a direct and positive impact on the market.

For instance, in 2023, the National Kidney Foundation (NKF) announced its latest investment through the NKF's Innovation Fund in Klinrisk, an artificial intelligence-based medical device company. Klinrisk is dedicated to transforming the early identification and management of high-risk chronic kidney disease (CKD) through accurate clinical risk prediction and decision support.

In 2023, Healthy.io, the global leader in transforming the smartphone camera into a clinical-grade device, announced that it completed a USD 50 million investment. This investment, together with a previously unannounced USD 45 million February 2022 investment, comprise the company's Series D. The company has seen increased commercial traction in the United States since July 2022, when it became the first and only company to offer an FDA-cleared smartphone-powered, at-home kidney test. Likewise, this Series D funding round is led by Schusterman Family Investments and is joined by Aleph and other existing shareholders. This investment, together with a previously unannounced USD 45 million February 2022 investment, comprise the company's Series D. The company has seen increased commercial traction in the United States since July 2022, when it became the first and only company to offer an FDA-cleared smartphone-powered, at-home kidney test.

In 2021, Monogram Health, a benefit management and care delivery company transforming care for individuals with chronic kidney and end-stage renal disease, announced that it closed a USD 160 million Series B funding round led by TPG Capital, the private equity platform of global alternative asset firm TPG.

In 2020, The Australian Government invested almost USD 35 million in Indigenous health projects including Indigenous blindness, deafness and chronic kidney disease.

Cystatin C assays offer the capability of detecting kidney dysfunction at an earlier stage, which is crucial for implementing interventions and treatments to slow down or manage the progression of kidney diseases. Additionally, cystatin C testing provides a means for monitoring kidney function over time. A result of the rising incidences of kidney diseases across the globe is expected to drive the demand of Cystatin assay market.

Restraint: High Development Costs of cystatin C assay

The cost of research, development, and validation of cystatin C assays can be a barrier for smaller diagnostic companies. Moreover, the costs associated with developing, producing, and implementing cystatin C assays, along with the required equipment and training, can pose a financial challenge for some healthcare facilities, especially in resource-constrained settings. For instance, the cost, accessibility, and the level of clinical awareness and understanding of test results. Cystatin C testing is approximately ten times more costly than creatinine testing, with a price of GBP 2.50 (USD 3.00) per test compared to GBP 0.25 (USD 0.30) for creatinine (Source: PubMed 2023).  Likewise, CysC assays can run on standard analyzers housed in most laboratories, CysC and sCr testing have similar labor costs. However, CysC reagents cost around USD 5–USD 10 per test compared with around USD 0.50 per test for sCr within the US; this cost differential will likely decline as CysC testing increases. In cost simulations of implementing CysC testing using the Gentian assay in Canada, the cost was estimated to be USD 2.88 per test for 1200 tests per year versus USD 2.17 per test based on 10,000 tests per year.  Similarly, a cystatin C test may currently cost more than a serum creatinine assay, the price of the former is not prohibitive. At Karger's institution, the University of Minnesota, a serum creatinine test costs about USD 2.50, while a cystatin C assay runs about USD 10.60 (Source: Medscape 2021).

Opportunity: Importance of companion diagnostics

Companion diagnostics include tests or assays intended to assist healthcare providers in making treatment decisions for patients based on the best response to therapy. The co-development of companion diagnostics with therapeutic products can significantly alter the drug development process and commercialize drug candidates by yielding safer drugs with enhanced therapeutic efficacy quickly and cost-effectively. With an increase in the demand for high-priced specialist therapies and safer drugs, the market for companion diagnostics is expected to showcase a high growth potential. The growing importance of companion diagnostics provides growth opportunities for the overall diagnostics market and the market.

Cystatin C, a protein that plays a role in inhibiting certain enzymes, has garnered interest in cancer research due to its potential implications in various aspects of cancer development, progression, and treatment response. In addition, pharmaceutical companies are increasingly collaborating with diagnostic companies to make safer and more effective drugs. On July 8, 2020, Thermo Fisher Scientific, Inc. (US) signed a Companion Diagnostic Agreement with Chugai Pharmaceutical Co., Ltd., (Japan), a Roche Group member. The company has also applied to the Ministry of Health, Labour and Welfare (MHLW) to elevate the use of the Oncomine Dx Target assay in Japan. Similarly, Cystatin C assay has gained importance in companion diagnostics, particularly in the field of nephrology and kidney-related diseases. Cystatin C is a sensitive and reliable marker of kidney function. It is particularly useful for the early detection and monitoring of kidney diseases, including chronic kidney disease (CKD). Companion diagnostics that include Cystatin C assays can help identify kidney dysfunction at an earlier stage, allowing for prompt intervention and management

Challenge: Dearth of skilled professionals

The scarcity of skilled professionals in the market is indeed a challenge that can affect the effective implementation and adoption of this diagnostic tool. The field of diagnostic testing requires trained personnel who can perform assays accurately, interpret results, troubleshoot technical issues, and ensure quality control. The dearth of a skilled workforce has been a challenge for several decades, resulting in an aging workforce and declining enrolment in training programs. It takes almost five to ten years of continuous practice in clinical laboratory work for technicians to gain expertise.

Europe and the UK have already reported low numbers of clinical technicians. The Gatsby Foundation stated in 2019 that over 1.5 million people serve in the health, engineering, science, and technology domains. Over 50,000 retire every year, and 700,000 technicians will be required to meet the soaring demands in the next decade. The Duquesne University School of Nursing has stated that by 2025, there will be a shortage of over 29,400 nurse practitioners and more than 400,000 home health aides

Ecosystem Analysis of Cystatin C Assay Market

An ecosystem analysis of the cystatin C assay would involve examining the various stakeholders, components, and interactions within the ecosystem that contribute to the development, adoption, and utilization of cystatin C assays in clinical and research settings. Moreover, an ecosystem analysis of the cystatin C assay helps stakeholders understand the dynamics, challenges, and opportunities within this healthcare sector. Collaboration among stakeholders and ongoing efforts to address challenges can contribute to the advancement of cystatin C testing and its impact on patient care and research.

Cystatin C  Assay Market Ecosystem

Based on product, the cystatin C assay market is segmented into analyzers, kits, and reagents. The reagents segment is expected to account the second largest shares during the forecast period. The demand for separate reagents is driven by the specific needs of clinical laboratories and research institutions. Separate reagents are also used in clinical laboratories and research settings. The availability of high-quality reagents is crucial for accurate and consistent cystatin C measurements, ultimately contributing to the overall growth of the market.

Based on method, the cystatin C assay market is segmented into Enzyme-Linked Immunosorbent Assay (ELISA), Particle-Enhanced Turbidimetric Immunoassay (PETIA), Particle-enhanced Nephelometric Immunoassay (PENIA), Chemiluminescent immunoassay (CLIA), Immunofluorescence assay (IFA), and Others. The PETIA segment accounted for the second largest share the market in 2022 due its advantages such as many clinical laboratories prefer automated methods like PETIA because they can be easily integrated into clinical chemistry analyzers, offering efficiency and reducing the potential for manual errors. The demand for cystatin C assay methods, as PETIA, continues to be driven by the need for precise and reliable measurements in the diagnosis and monitoring of kidney function, particularly in the context of chronic kidney disease (CKD) and related conditions.

Market Segments of Cystatin C Assay Market

US accounted for the largest share of the North American cystatin c assay industry in 2022.

Based on the region, the North American cystatin c assay market is segmented into US and Canada. In 2022, the US accounted for the largest share of the North American market. Growth in this market can be attributed to presence of stringent regulatory standard, rising healthcare expenditure, the increasing number of chronic kidney diseases, the rising geriatric population, and the strong presence of cystatin c assay manufacturers.

Cystatin C  Assay Market by Region

To know about the assumptions considered for the study, download the pdf brochure

India registered the second highest growth rate in Asia Pacific cystatin C assay industry.

The APAC cystatin C assay market is segmented into Japan, China, India, and Rest of Apac. In 2022, India accounted for the second highest growth rate of the Asian market. The second high growth rate of India can be attributed to the increasing awareness of health issues, and rising healthcare expenditure, rising of a medical tourism and the increasing geriatric population. An increase in the number of elderly people gives rise to various nephros diseases. Therefore, growth in this population segment will directly drive the demand for cystatin C assay products.

The France in European cystatin C assay industry to witness the second highest shares during the forecast period.

The Europe cystatin C assay market is segmented into Germany, France, the UK, Italy, Spain and the Rest of Europe. France is registered the second highest shares during the forecast period. The major factors contributing to the growth of this market are the high prevalence of old age population, rising in kindey diseases, increasing R&D activities, strategic developments by key players. Clinical laboratories and diagnostic centers are key users of cystatin C assays in France. These facilities perform a wide range of diagnostic tests, including kidney function assessments, contributing to the demand for cystatin C assays.

Some of the major players operating in this market are Abbott (US), Roche Diagnostics Limited.(Switzerland), Siemens Healthcare GmbH (Germany),Thermo Fisher Scientific Inc. (US), Randox Laboratories Ltd. (UK), DiaSys Diagnostic Systems GmbH (Germany), Bio-Techne (US), Gentian Diagnostics ASA (Norway), Getein Biotech, Inc. (China), Agilent Technologies, Inc. (US), Abcam plc. (UK), Sino Biological, Inc. (China), Eurolyser Diagnostica GmbH (Austria).

In 2022, Roche Diagnostics Limited. (Switzerland), held the leading position in the market. The company’s large share can be attributed to broad usage of its analyzers and strong global presence. Abbott (US), held the second position in the cystatin c assay market in 2022.

Scope of the Cystatin C Assay Industry:

Report Metric

Details

Market Revenue in 2023

$377 million

Estimated Value by 2028

$540 million

Revenue Rate

Poised to grow at a CAGR of 7.5%

Market Driver

Rising Prevalence of Kidney Diseases

Market Opportunity

Importance of companion diagnostics

This research report categorizes the cystatin C assay market to forecast revenue and analyze trends in each of the following submarkets:

SEGMENTS

INCLUSIONS

Product

  • Analyzers
  • Kits
  • Reagents

Method

  • Enzyme-Linked Immunosorbent Assay (ELISA)
  • Particle-Enhanced Turbidimetric Immunoassay (PETIA)
  • Particle-enhanced Nephelometric Immunoassay (PENIA) 
  • Chemiluminescent immunoassay (CLIA)
  • Immunofluorescence assay (IFA)
  • Others

Sample Type

  • Blood
  • Urine

Application

  • Diagnostics
  • Research

End User

  • Hospitals
  • Clinical Laboratories
  • Pharmaceutical and Biotechnology Companies & CROs & Academic research institutes

Region

  • North America
  • Europe
  • Apac
  • Rest of the World

Recent Developments of Cystatin C Assay Industry

  • September 2022, Gentian Cystatin C and GCAL assays received IVDR (In-Vitro Diagnostic Regulation) by TüV SÜD.
  • March 2021, Roche acquired GenMark Diagnostics at USD 24.05 per share and a total transactional value of USD 1.8 billion. The acquisition strengthened Roche’s Diagnostics portfolio.

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

TABLE OF CONTENTS
 
1 INTRODUCTION (Page No. - 30)
    1.1 STUDY OBJECTIVES 
    1.2 MARKET DEFINITION 
           1.2.1 INCLUSIONS & EXCLUSIONS
    1.3 MARKET SCOPE 
           1.3.1 REGIONAL SCOPE
           1.3.2 YEARS CONSIDERED
    1.4 CURRENCY CONSIDERED 
    1.5 UNITS CONSIDERED 
    1.6 STAKEHOLDERS 
    1.7 RECESSION IMPACT 
 
2 RESEARCH METHODOLOGY (Page No. - 35)
    2.1 RESEARCH DATA 
          FIGURE 1 RESEARCH DESIGN
           2.1.1 SECONDARY DATA
                    2.1.1.1 Secondary sources
           2.1.2 PRIMARY DATA
                    2.1.2.1 Key data from primary sources
                    2.1.2.2 Key industry insights
                                FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
                                FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS
    2.2 MARKET SIZE ESTIMATION 
           2.2.1 BOTTOM-UP APPROACH
                    FIGURE 4 MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH
           2.2.2 BOTTOM-UP APPROACH: NUMBER OF TEST-BASED ANALYSES
                    FIGURE 5 MARKET SIZE ESTIMATION: TOP-DOWN APPROACH
                    FIGURE 6 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
    2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 
          FIGURE 7 DATA TRIANGULATION METHODOLOGY
    2.4 RESEARCH ASSUMPTIONS 
    2.5 RISK ASSESSMENT 
          TABLE 1 RISK ASSESSMENT: GLOBAL MARKET
    2.6 RESEARCH LIMITATIONS 
           2.6.1 METHODOLOGY-RELATED LIMITATIONS
           2.6.2 SCOPE-RELATED LIMITATIONS
    2.7 GROWTH RATE ASSUMPTIONS 
    2.8 RECESSION IMPACT ANALYSIS 
 
3 EXECUTIVE SUMMARY (Page No. - 48)
    FIGURE 8 CYSTATIN C ASSAY MARKET, BY PRODUCT, 2023 VS. 2028 (USD MILLION)
    FIGURE 9 CYSTATIN C ASSAY INDUSTRY, BY METHOD, 2023 VS. 2028 (USD MILLION)
    FIGURE 10 MARKET, BY APPLICATION, 2023 VS. 2028 (USD MILLION)
    FIGURE 11 MARKET, BY SAMPLE TYPE, 2023 VS. 2028 (USD MILLION)
    FIGURE 12 MARKET, BY END USER, 2023 VS. 2028 (USD MILLION)
    FIGURE 13 REGIONAL SNAPSHOT: GLOBAL MARKET
 
4 PREMIUM INSIGHTS (Page No. - 53)
    4.1 ATTRACTIVE OPPORTUNITIES FOR PLAYERS IN CYSTATIN C ASSAY MARKET 
          FIGURE 14 INCREASING PREVALENCE OF KIDNEY DISEASES AND GROWING GERIATRIC POPULATION TO DRIVE MARKET
    4.2 NORTH AMERICA: CYSTATIN C ASSAY INDUSTRY, BY PRODUCT 
          FIGURE 15 KITS ACCOUNTED FOR LARGEST SHARE, BY PRODUCT, IN NORTH AMERICA
    4.3 MARKET: REGIONAL MIX 
          FIGURE 16 ASIA PACIFIC MARKET TO WITNESS FASTEST GROWTH DURING FORECAST PERIOD
    4.4 MARKET: DEVELOPED VS. EMERGING ECONOMIES 
          FIGURE 17 DEVELOPING ECONOMIES TO REGISTER HIGHER GROWTH DURING FORECAST PERIOD
    4.5 REGIONAL GROWTH OPPORTUNITIES IN MARKET 
          FIGURE 18 CHINA TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD
 
5 MARKET OVERVIEW (Page No. - 57)
    5.1 INTRODUCTION 
    5.2 MARKET DYNAMICS 
          FIGURE 19 CYSTATIN C ASSAY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES,  AND CHALLENGES
           5.2.1 DRIVERS
                    5.2.1.1 Rising prevalence of kidney diseases
                    5.2.1.2 Growing geriatric population
                                TABLE 2 GERIATRIC POPULATION, BY REGION, 2015 VS. 2030 VS. 2050 (MILLION)
                                TABLE 3 ESTIMATED INCREASE IN GERIATRIC POPULATION, BY REGION (2019–2050)
                    5.2.1.3 Recent advancements in chemiluminescence immunoassay technologies
                    5.2.1.4 Growth in biotechnology and biopharmaceutical industries
                    5.2.1.5 Increasing adoption of POC testing
                                TABLE 4 POC ANALYSIS DEVICES
                    5.2.1.6 Supportive government policies
           5.2.2 RESTRAINTS
                    5.2.2.1 Stringent requirements for approval of cystatin C assay instruments and consumables
                    5.2.2.2 High development costs of cystatin C assays
                                TABLE 5 CYSTATIN C CONSUMABLES AND INSTRUMENTS
           5.2.3 OPPORTUNITIES
                    5.2.3.1 Growth opportunities in emerging economies
                    5.2.3.2 Importance of companion diagnostics
                                TABLE 6 APPROVED AND LAUNCHED COMPANION DIAGNOSTIC ASSAYS
                    5.2.3.3 Development of condition-specific biomarkers and tests
           5.2.4 CHALLENGES
                    5.2.4.1 Dearth of skilled professionals
    5.3 REGULATORY OVERVIEW 
           5.3.1 US
                    FIGURE 20 US: REGULATORY PROCESS FOR IVD DEVICES
           5.3.2 CANADA
                    FIGURE 21 CANADA: REGULATORY PROCESS FOR IVD DEVICES IN CANADA
           5.3.3 EUROPE
                    TABLE 7 EUROPE: CLASSIFICATION OF IVD DEVICES
           5.3.4 JAPAN
                    5.3.4.1 Japan: Regulatory process for IVD devices
                                TABLE 8 JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
           5.3.5 CHINA
                    TABLE 9 CHINA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
           5.3.6 INDIA
                    5.3.6.1 India: Regulatory process for IVD devices
           5.3.7 INDONESIA
                    TABLE 10 INDONESIA: REGISTRATION PROCESS FOR IVD DEVICES
           5.3.8 RUSSIA
                    TABLE 11 RUSSIA: CLASSIFICATION OF IVD DEVICES
           5.3.9 SAUDI ARABIA
                    TABLE 12 SAUDI ARABIA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
           5.3.10 MEXICO
                    5.3.10.1 Mexico: Regulatory process for IVD devices
                                 TABLE 13 MEXICO: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
           5.3.11 BRAZIL
                    5.3.11.1 Brazil: Regulatory process for IVD devices
           5.3.12 SOUTH KOREA
                     TABLE 14 SOUTH KOREA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
           5.3.13 MIDDLE EAST
           5.3.14 AFRICA
    5.4 TECHNOLOGY ANALYSIS 
          TABLE 15 NON-GFR DETERMINANTS OF SERUM CREATININE AND CYSTATIN C
          TABLE 16 RECENT PRODUCT LAUNCHES WITH ADVANCED TECHNOLOGIES IN CYSTATIN C ASSAY INDUSTRY
    5.5 TRADE ANALYSIS 
           5.5.1 TRADE ANALYSIS FOR IMMUNOASSAYS
                    TABLE 17 IMPORT DATA FOR HS CODE 902750, BY COUNTRY, 2018–2022 (USD THOUSAND)
                    TABLE 18 EXPORT DATA FOR HS CODE 902750, BY COUNTRY, 2018–2022 (USD THOUSAND)
    5.6 PATENT ANALYSIS 
    5.7 VALUE CHAIN ANALYSIS 
          FIGURE 22 VALUE CHAIN ANALYSIS: MAJOR VALUE ADDED DURING MANUFACTURING AND ASSEMBLY PHASES
    5.8 SUPPLY CHAIN ANALYSIS 
          FIGURE 23 DIRECT DISTRIBUTION—PREFERRED STRATEGY FOR PROMINENT COMPANIES
    5.9 ECOSYSTEM ANALYSIS OF MARKET 
          FIGURE 24 ECOSYSTEM ANALYSIS OF MARKET
           5.9.1 ROLE OF COMPANIES IN ECOSYSTEM
           5.9.2 KEY PLAYERS OPERATING IN MARKET
    5.10 PORTER’S FIVE FORCES ANALYSIS 
           TABLE 19 IMPACT OF PORTER’S FIVE FORCES ON MARKET
           5.10.1 INTENSITY OF COMPETITIVE RIVALRY
           5.10.2 BARGAINING POWER OF SUPPLIERS
           5.10.3 BARGAINING POWER OF BUYERS
           5.10.4 THREAT OF SUBSTITUTES
           5.10.5 THREAT OF NEW ENTRANTS
    5.11 KEY CONFERENCES & EVENTS (2023–2024) 
           TABLE 20 LIST OF CONFERENCES AND EVENTS (2023–2024)
    5.12 PRICING ANALYSIS 
           TABLE 21 CYSTATIN C ASSAY: PRICE RANGE FOR CYSTATIN C ASSAY PRODUCTS
           TABLE 22 AVERAGE SELLING PRICE OF PRODUCTS OFFERED BY KEY PLAYERS (2022)
    5.13 KEY STAKEHOLDERS & BUYING CRITERIA 
           5.13.1 KEY STAKEHOLDERS IN BUYING PROCESS
                     FIGURE 25 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY END USER
                     TABLE 23 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR END USERS
           5.13.2 BUYING CRITERIA
                     FIGURE 26 KEY BUYING CRITERIA FOR TOP END USERS
                     TABLE 24 KEY BUYING CRITERIA, BY END USER
    5.14 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS 
 
6 CYSTATIN C ASSAY MARKET, BY PRODUCT (Page No. - 94)
    6.1 INTRODUCTION 
          TABLE 25 CYSTATIN C ASSAY INDUSTRY, BY PRODUCT, 2021–2028 (USD MILLION)
    6.2 KITS 
           6.2.1 WIDE USE OF KITS IN CLINICAL LABORATORIES, HEALTHCARE SETTINGS, AND RESEARCH INSTITUTIONS TO DRIVE MARKET
                    TABLE 26 CYSTATIN C ASSAY KITS AVAILABLE IN MARKET
                    TABLE 27 CYSTATIN C ASSAY KITS MARKET, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 28 CYSTATIN C ASSAY KITS MARKET, BY NORTH AMERICAN COUNTRIES,  2021–2028 (USD MILLION)
                    TABLE 29 CYSTATIN C ASSAY KITS MARKET, BY EUROPEAN COUNTRIES, 2021–2028 (USD MILLION)
                    TABLE 30 CYSTATIN C ASSAY KITS MARKET, BY ASIA PACIFIC COUNTRIES,  2021–2028 (USD MILLION)
           6.2.2 REAGENTS
                    6.2.2.1 Wide use in diagnostic, research, and high-throughput screening to drive market
                    TABLE 31 CYSTATIN C ASSAY REAGENTS AVAILABLE IN MARKET
                    TABLE 32 CYSTATIN C REAGENTS MARKET, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 33 CYSTATIN C ASSAY REAGENTS MARKET, BY NORTH AMERICAN COUNTRIES,  2021–2028 (USD MILLION)
                    TABLE 34 CYSTATIN C ASSAY REAGENTS MARKET, BY EUROPEAN COUNTRIES,  2021–2028 (USD MILLION)
                    TABLE 35 CYSTATIN C ASSAY REAGENTS MARKET, BY ASIA PACIFIC COUNTRIES,  2021–2028 (USD MILLION)
    6.3 ANALYZERS 
           6.3.1 INCREASING NUMBER OF HOSPITALS AND CLINICAL LABORATORIES TO DRIVE MARKET
                    TABLE 36 CYSTATIN C ASSAY ANALYZERS AVAILABLE IN MARKET
                    TABLE 37 CYSTATIN C ASSAY ANALYZERS MARKET, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 38 CYSTATIN C ASSAY ANALYZERS MARKET, BY NORTH AMERICAN COUNTRIES,  2021–2028 (USD MILLION)
                    TABLE 39 CYSTATIN C ASSAY ANALYZERS MARKET, BY EUROPEAN COUNTRIES,  2021–2028 (USD MILLION)
                    TABLE 40 CYSTATIN C ASSAY ANALYZERS MARKET, BY ASIA PACIFIC COUNTRIES,  2021–2028 (USD MILLION)
 
7 CYSTATIN C ASSAY MARKET, BY METHOD (Page No. - 105)
    7.1 INTRODUCTION 
          TABLE 41 CYSTATIN C ASSAY INDUSTRY, BY METHOD, 2021–2028 (USD MILLION)
    7.2 ENZYME-LINKED IMMUNOSORBENT ASSAY 
           7.2.1 WIDE ROLE IN DIAGNOSIS, PROGNOSIS, AND MONITORING OF VARIOUS RENAL DISEASES TO DRIVE MARKET
                    TABLE 42 ENZYME-LINKED IMMUNOSORBENT ASSAY: MARKET, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 43 ENZYME-LINKED IMMUNOSORBENT ASSAY: MARKET, BY NORTH AMERICAN COUNTRIES, 2021–2028 (USD MILLION)
                    TABLE 44 ENZYME-LINKED IMMUNOSORBENT ASSAY: MARKET, BY EUROPEAN COUNTRIES, 2021–2028 (USD MILLION)
                    TABLE 45 ENZYME-LINKED IMMUNOSORBENT ASSAY: MARKET, BY ASIA PACIFIC COUNTRIES, 2021–2028 (USD MILLION)
    7.3 PARTICLE-ENHANCED TURBIDIMETRIC IMMUNOASSAY 
           7.3.1 APPLICATION OF PETIA TECHNOLOGY IN ALL CLINICAL ANALYZERS TO DRIVE MARKET
                    TABLE 46 PARTICLE-ENHANCED TURBIDIMETRIC IMMUNOASSAY: MARKET,  BY REGION, 2021–2028 (USD MILLION)
                    TABLE 47 PARTICLE-ENHANCED TURBIDIMETRIC IMMUNOASSAY: MARKET,  BY NORTH AMERICAN COUNTRIES, 2021–2028 (USD MILLION)
                    TABLE 48 PARTICLE-ENHANCED TURBIDIMETRIC IMMUNOASSAY: MARKET,  BY EUROPEAN COUNTRIES, 2021–2028 (USD MILLION)
                    TABLE 49 PARTICLE-ENHANCED TURBIDIMETRIC IMMUNOASSAY: MARKET,  BY ASIA PACIFIC COUNTRIES, 2021–2028 (USD MILLION)
    7.4 IMMUNOFLUORESCENCE ASSAY 
           7.4.1 WIDE USE OF IMMUNOFLUORESCENCE ASSAY IN DIAGNOSIS OF ANTIBODIES IMMUNOLOGY AND CELL BIOLOGY RESEARCH TO DRIVE MARKET
                    TABLE 50 IMMUNOFLUORESCENCE ASSAY: MARKET, BY REGION,  2021–2028 (USD MILLION)
                    TABLE 51 IMMUNOFLUORESCENCE ASSAY: MARKET, BY NORTH AMERICAN COUNTRIES, 2021–2028 (USD MILLION)
                    TABLE 52 IMMUNOFLUORESCENCE ASSAY: MARKET, BY EUROPEAN COUNTRIES, 2021–2028 (USD MILLION)
                    TABLE 53 IMMUNOFLUORESCENCE ASSAY: MARKET, BY ASIA PACIFIC COUNTRIES, 2021–2028 (USD MILLION)
    7.5 CHEMILUMINESCENT IMMUNOASSAY 
           7.5.1 ACCESSIBILITY TO MANY CLINICAL LABORATORIES TO INCREASE DEMAND
                    TABLE 54 CHEMILUMINESCENT IMMUNOASSAY: MARKET, BY REGION,  2021–2028 (USD MILLION)
                    TABLE 55 CHEMILUMINESCENT IMMUNOASSAY: MARKET, BY NORTH AMERICAN COUNTRIES, 2021–2028 (USD MILLION)
                    TABLE 56 CHEMILUMINESCENT IMMUNOASSAY: MARKET, BY EUROPEAN COUNTRIES, 2021–2028 (USD MILLION)
                    TABLE 57 CHEMILUMINESCENT IMMUNOASSAY: MARKET, BY ASIA PACIFIC COUNTRIES, 2021–2028 (USD MILLION)
    7.6 PARTICLE-ENHANCED NEPHELOMETRIC IMMUNOASSAY 
           7.6.1 PRECISION AND AUTOMATION CAPABILITIES IN CLINICAL LABORATORIES TO DRIVE MARKET
                    TABLE 58 PARTICLE-ENHANCED NEPHELOMETRIC IMMUNOASSAY: MARKET,  BY REGION, 2021–2028 (USD MILLION)
                    TABLE 59 PARTICLE-ENHANCED NEPHELOMETRIC IMMUNOASSAY: MARKET, BY NORTH AMERICAN COUNTRIES, 2021–2028 (USD MILLION)
                    TABLE 60 PARTICLE-ENHANCED NEPHELOMETRIC IMMUNOASSAY: MARKET,  BY EUROPEAN COUNTRIES, 2021–2028 (USD MILLION)
                    TABLE 61 PARTICLE-ENHANCED NEPHELOMETRIC IMMUNOASSAY: MARKET,  BY ASIA PACIFIC COUNTRIES, 2021–2028 (USD MILLION)
    7.7 OTHER METHODS 
          TABLE 62 OTHER METHODS: MARKET, BY REGION, 2021–2028 (USD MILLION)
          TABLE 63 OTHER METHODS: MARKET, BY NORTH AMERICAN COUNTRIES,  2021–2028 (USD MILLION)
          TABLE 64 OTHER METHODS: MARKET, BY EUROPEAN COUNTRIES,  2021–2028 (USD MILLION)
          TABLE 65 OTHER METHODS: MARKET, BY ASIA PACIFIC COUNTRIES,  2021–2028 (USD MILLION)
 
8 CYSTATIN C ASSAY MARKET, BY SAMPLE TYPE (Page No. - 123)
    8.1 INTRODUCTION 
          TABLE 66 CYSTATIN C ASSAY INDUSTRY, BY SAMPLE TYPE, 2021–2028 (USD MILLION)
    8.2 BLOOD 
           8.2.1 RISING PREVALENCE OF CHRONIC CONDITIONS TO DRIVE MARKET
                    TABLE 67 BLOOD: MARKET, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 68 BLOOD: MARKET, BY NORTH AMERICAN COUNTRIES,  2021–2028 (USD MILLION)
                    TABLE 69 BLOOD: MARKET, BY EUROPEAN COUNTRIES,  2021–2028 (USD MILLION)
                    TABLE 70 BLOOD: MARKET, BY ASIA PACIFIC COUNTRIES,  2021–2028 (USD MILLION)
    8.3 URINE 
           8.3.1 RESEARCH APPLICATION OF URINE CYSTATIN C IN CLINICAL INVESTIGATION TO DRIVE MARKET
                    TABLE 71 URINE: MARKET, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 72 URINE: MARKET, BY NORTH AMERICAN COUNTRIES,  2021–2028 (USD MILLION)
                    TABLE 73 URINE: MARKET, BY EUROPEAN COUNTRIES,  2021–2028 (USD MILLION)
                    TABLE 74 URINE: MARKET, BY ASIA PACIFIC COUNTRIES,  2021–2028 (USD MILLION)
 
9 CYSTATIN C ASSAY MARKET, BY APPLICATION (Page No. - 130)
    9.1 INTRODUCTION 
          TABLE 75 CYSTATIN C ASSAY INDUSTRY, BY APPLICATION, 2021–2028 (USD MILLION)
    9.2 DIAGNOSTICS 
           9.2.1 WIDE USE OF CYSTATIN C ASSAYS IN DIAGNOSTICS TO DRIVE MARKET
                    TABLE 76 DIAGNOSTICS: MARKET, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 77 DIAGNOSTICS: MARKET, BY NORTH AMERICAN COUNTRIES,  2021–2028 (USD MILLION)
                    TABLE 78 DIAGNOSTICS: MARKET, BY EUROPEAN COUNTRIES,  2021–2028 (USD MILLION)
                    TABLE 79 DIAGNOSTICS: MARKET, BY ASIA PACIFIC COUNTRIES,  2021–2028 (USD MILLION)
    9.3 RESEARCH 
           9.3.1 USE OF CYSTATIN C ASSAYS IN SCIENTIFIC STUDIES, CLINICAL TRIALS, AND BIOMARKER RESEARCH TO BOOST MARKET
                    TABLE 80 RESEARCH: MARKET, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 81 RESEARCH: MARKET, BY NORTH AMERICAN COUNTRIES,  2021–2028 (USD MILLION)
                    TABLE 82 RESEARCH: MARKET, BY EUROPEAN COUNTRIES,  2021–2028 (USD MILLION)
                    TABLE 83 RESEARCH: MARKET, BY ASIA PACIFIC COUNTRIES,  2021–2028 (USD MILLION)
 
10 CYSTATIN C ASSAY MARKET, BY END USER (Page No. - 137)
     10.1 INTRODUCTION 
             TABLE 85 CYSTATIN C ASSAY INDUSTRY, BY END USER, 2021–2028 (USD MILLION)
     10.2 HOSPITALS 
             10.2.1 GROWING PATIENT POPULATION TO DRIVE MARKET
                        TABLE 86 MARKET FOR HOSPITALS, BY REGION, 2021–2028 (USD MILLION)
                        TABLE 87 MARKET FOR HOSPITALS, BY NORTH AMERICAN COUNTRIES,  2021–2028 (USD MILLION)
                        TABLE 88 MARKET FOR HOSPITALS, BY EUROPEAN COUNTRIES,  2021–2028 (USD MILLION)
                        TABLE 89 MARKET FOR HOSPITALS, BY ASIA PACIFIC COUNTRIES,  2021–2028 (USD MILLION)
     10.3 CLINICAL LABORATORIES 
             10.3.1 RISING CLINICAL TEST VOLUMES AND REQUIREMENTS TO BOOST USE OF CYSTATIN C ASSAYS
                        TABLE 90 MARKET FOR CLINICAL LABORATORIES, BY REGION,  2021–2028 (USD MILLION)
                        TABLE 91 MARKET FOR CLINICAL LABORATORIES, BY NORTH AMERICAN COUNTRIES, 2021–2028 (USD MILLION)
                        TABLE 92 MARKET FOR CLINICAL LABORATORIES, BY EUROPEAN COUNTRIES, 2021–2028 (USD MILLION)
                        TABLE 93 MARKET FOR CLINICAL LABORATORIES, BY ASIA PACIFIC COUNTRIES, 2021–2028 (USD MILLION)
     10.4 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, CONTRACT RESEARCH ORGANIZATIONS, AND ACADEMIC RESEARCH INSTITUTES 
             10.4.1 GROWING DRUG DISCOVERY AND CLINICAL STUDY AND RISING NUMBER OF COLLEGES & UNIVERSITIES TO DRIVE DEMAND
                        TABLE 94 MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, CROS, AND ACADEMIC RESEARCH INSTITUTES, BY REGION, 2021–2028 (USD MILLION)
                        TABLE 95 MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, CROS, AND ACADEMIC RESEARCH INSTITUTES, BY NORTH AMERICAN COUNTRIES, 2021–2028 (USD MILLION)
                        TABLE 96 MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, CROS, AND ACADEMIC RESEARCH INSTITUTES, BY EUROPEAN COUNTRIES, 2021–2028 (USD MILLION)
                        TABLE 97 MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, CROS, AND ACADEMIC RESEARCH INSTITUTES, BY ASIA PACIFIC COUNTRIES,  2021–2028 (USD MILLION)
 
11 CYSTATIN C ASSAY MARKET, BY REGION (Page No. - 147)
     11.1 INTRODUCTION 
             TABLE 98 CYSTATIN C ASSAY INDUSTRY, BY REGION, 2021–2028 (USD MILLION)
     11.2 NORTH AMERICA 
             FIGURE 27 NORTH AMERICA: CYSTATIN C ASSAY MARKET SNAPSHOT
             TABLE 99 NORTH AMERICA: MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
             TABLE 100 NORTH AMERICA: MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
             TABLE 101 NORTH AMERICA: MARKET, BY METHOD,  2021–2028 (USD MILLION)
             TABLE 102 NORTH AMERICA: MARKET, BY APPLICATION,  2021–2028 (USD MILLION)
             TABLE 103 NORTH AMERICA: MARKET, BY SAMPLE TYPE,  2021–2028 (USD MILLION)
             TABLE 104 NORTH AMERICA: MARKET, BY END USER,  2021–2028 (USD MILLION)
             11.2.1 RECESSION IMPACT ON NORTH AMERICA
             11.2.2 US
                        11.2.2.1 US to account for largest market share in North America
                                      TABLE 105 US: KEY MACRO INDICATORS
                                      TABLE 106 US: CYSTATIN C ASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                                      TABLE 107 US: MARKET, BY METHOD, 2021–2028 (USD MILLION)
                                      TABLE 108 US: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 109 US: MARKET, BY SAMPLE TYPE, 2021–2028 (USD MILLION)
                                      TABLE 110 US: MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.2.3 CANADA
                        11.2.3.1 Government initiatives to support market growth
                                      TABLE 111 CANADA: KEY MACRO INDICATORS
                                      TABLE 112 CANADA: CYSTATIN C ASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                                      TABLE 113 CANADA: MARKET, BY METHOD, 2021–2028 (USD MILLION)
                                      TABLE 114 CANADA: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 115 CANADA: MARKET, BY SAMPLE TYPE, 2021–2028 (USD MILLION)
                                      TABLE 116 CANADA: MARKET, BY END USER, 2021–2028 (USD MILLION)
     11.3 EUROPE 
            TABLE 117 EUROPE: HEALTHCARE EXPENDITURE, BY COUNTRY (% OF GDP)
             11.3.1 RECESSION IMPACT ON EUROPE
                        TABLE 118 EUROPE: CYSTATIN C ASSAY MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                        TABLE 119 EUROPE: MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                        TABLE 120 EUROPE: MARKET, BY METHOD,  2021–2028 (USD MILLION)
                        TABLE 121 EUROPE: MARKET, BY APPLICATION,  2021–2028 (USD MILLION)
                        TABLE 122 EUROPE: MARKET, BY SAMPLE TYPE,  2021–2028 (USD MILLION)
                        TABLE 123 EUROPE: MARKET, BY END USER,  2021–2028 (USD MILLION)
             11.3.2 GERMANY
                        11.3.2.1 High healthcare spending to drive market
                                      TABLE 124 GERMANY: KEY MACRO INDICATORS
                                      TABLE 125 GERMANY: CYSTATIN C ASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                                      TABLE 126 GERMANY: MARKET, BY METHOD,  2021–2028 (USD MILLION)
                                      TABLE 127 GERMANY: MARKET, BY APPLICATION,  2021–2028 (USD MILLION)
                                      TABLE 128 GERMANY: MARKET, BY SAMPLE TYPE,  2021–2028 (USD MILLION)
                                      TABLE 129 GERMANY: MARKET, BY END USER,  2021–2028 (USD MILLION)
             11.3.3 FRANCE
                        11.3.3.1 Presence of favorable reimbursement policies to make market lucrative
                                      TABLE 130 FRANCE: KEY MACRO INDICATORS
                                      TABLE 131 FRANCE: CYSTATIN C ASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                                      TABLE 132 FRANCE: MARKET, BY METHOD,  2021–2028 (USD MILLION)
                                      TABLE 133 FRANCE: MARKET, BY APPLICATION,  2021–2028 (USD MILLION)
                                      TABLE 134 FRANCE: MARKET, BY SAMPLE TYPE,  2021–2028 (USD MILLION)
                                      TABLE 135 FRANCE: MARKET, BY END USER,  2021–2028 (USD MILLION)
             11.3.4 UK
                        11.3.4.1 Government support for disease diagnostics and favorable investment scenario to drive market
                                      TABLE 136 UK: CYSTATIN C ASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                                      TABLE 137 UK: MARKET, BY METHOD,  2021–2028 (USD MILLION)
                                      TABLE 138 UK: MARKET, BY APPLICATION,  2021–2028 (USD MILLION)
                                      TABLE 139 UK: MARKET, BY SAMPLE TYPE, 2021–2028 (USD MILLION)
                                      TABLE 140 UK: MARKET, BY END USER,  2021–2028 (USD MILLION)
             11.3.5 ITALY
                        11.3.5.1 Growing geriatric population and increasing support for research to boost market growth
                                      TABLE 141 ITALY: CYSTATIN C ASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                                      TABLE 142 ITALY: MARKET, BY METHOD, 2021–2028 (USD MILLION)
                                      TABLE 143 ITALY: MARKET, BY APPLICATION,  2021–2028 (USD MILLION)
                                      TABLE 144 ITALY: MARKET, BY SAMPLE TYPE,  2021–2028 (USD MILLION)
                                      TABLE 145 ITALY: MARKET, BY END USER,  2021–2028 (USD MILLION)
             11.3.6 SPAIN
                        11.3.6.1 Presence of well-established network of research centers, universities, and hospitals to drive market
                                      TABLE 146 SPAIN: CYSTATIN C ASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                                      TABLE 147 SPAIN: MARKET, BY METHOD,  2021–2028 (USD MILLION)
                                      TABLE 148 SPAIN: MARKET, BY APPLICATION,  2021–2028 (USD MILLION)
                                      TABLE 149 SPAIN: MARKET, BY SAMPLE TYPE,  2021–2028 (USD MILLION)
                                      TABLE 150 SPAIN: MARKET, BY END USER,  2021–2028 (USD MILLION)
             11.3.7 REST OF EUROPE
                        TABLE 151 REST OF EUROPE: HEALTHCARE EXPENDITURE, BY COUNTRY, 2010 VS. 2021 (% OF GDP)
                        TABLE 152 REST OF EUROPE: CYSTATIN C ASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                        TABLE 153 REST OF EUROPE: MARKET, BY METHOD,  2021–2028 (USD MILLION)
                        TABLE 154 REST OF EUROPE: MARKET, BY APPLICATION,  2021–2028 (USD MILLION)
                        TABLE 155 REST OF EUROPE: MARKET, BY SAMPLE TYPE,  2021–2028 (USD MILLION)
                        TABLE 156 REST OF EUROPE: MARKET, BY END USER,  2021–2028 (USD MILLION)
     11.4 ASIA PACIFIC 
             11.4.1 RECESSION IMPACT ON ASIA PACIFIC
                        FIGURE 28 ASIA PACIFIC: CYSTATIN C ASSAY MARKET SNAPSHOT
                        TABLE 157 ASIA PACIFIC: MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                        TABLE 158 ASIA PACIFIC: MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                        TABLE 159 ASIA PACIFIC: MARKET, BY METHOD,  2021–2028 (USD MILLION)
                        TABLE 160 ASIA PACIFIC: MARKET, BY APPLICATION,  2021–2028 (USD MILLION)
                        TABLE 161 ASIA PACIFIC: MARKET, BY SAMPLE TYPE,  2021–2028 (USD MILLION)
                        TABLE 162 ASIA PACIFIC: MARKET, BY END USER,  2021–2028 (USD MILLION)
             11.4.2 CHINA
                        11.4.2.1 High prevalence of diabetes and chronic kidney disease to drive market
                                      TABLE 163 CHINA: KEY MACRO INDICATORS
                                      TABLE 164 CHINA: CYSTATIN C ASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                                      TABLE 165 CHINA: MARKET, BY METHOD, 2021–2028 (USD MILLION)
                                      TABLE 166 CHINA: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 167 CHINA: MARKET, BY SAMPLE TYPE, 2021–2028 (USD MILLION)
                                      TABLE 168 CHINA: MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.4.3 INDIA
                        11.4.3.1 Growing medical tourism and healthcare infrastructure to drive market
                                      TABLE 169 INDIA: KEY MACRO INDICATORS
                                      TABLE 170 INDIA: CYSTATIN C ASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                                      TABLE 171 INDIA: MARKET, BY METHOD, 2021–2028 (USD MILLION)
                                      TABLE 172 INDIA: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 173 INDIA: MARKET, BY SAMPLE TYPE, 2021–2028 (USD MILLION)
                                      TABLE 174 INDIA: MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.4.4 JAPAN
                        11.4.4.1 Investments in healthcare technology and research to support growth
                                      TABLE 175 JAPAN: KEY MACRO INDICATORS
                                      TABLE 176 JAPAN: CYSTATIN C ASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                                      TABLE 177 JAPAN: MARKET, BY METHOD, 2021–2028 (USD MILLION)
                                      TABLE 178 JAPAN: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 179 JAPAN: MARKET, BY SAMPLE TYPE, 2021–2028 (USD MILLION)
                                      TABLE 180 JAPAN: MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.4.5 REST OF ASIA PACIFIC
                        TABLE 181 REST OF ASIA PACIFIC: DIABETES PREVALENCE (% OF POPULATION AGED 20–79), BY COUNTRY
                        TABLE 182 REST OF ASIA PACIFIC: CYSTATIN C ASSAY MARKET, BY PRODUCT,  2021–2028 (USD MILLION)
                        TABLE 183 REST OF ASIA PACIFIC: MARKET, BY METHOD,  2021–2028 (USD MILLION)
                        TABLE 184 REST OF ASIA PACIFIC: MARKET, BY APPLICATION,  2021–2028 (USD MILLION)
                        TABLE 185 REST OF ASIA PACIFIC: MARKET, BY SAMPLE TYPE,  2021–2028 (USD MILLION)
                        TABLE 186 REST OF ASIA PACIFIC: MARKET, BY END USER,  2021–2028 (USD MILLION)
     11.5 REST OF THE WORLD 
             TABLE 187 REST OF THE WORLD: POPULATION AGED 65 AND ABOVE (% OF TOTAL POPULATION)
             11.5.1 RECESSION IMPACT ON REST OF THE WORLD
                        TABLE 188 REST OF THE WORLD: CYSTATIN C ASSAY MARKET, BY PRODUCT,  2021–2028 (USD MILLION)
                        TABLE 189 REST OF THE WORLD: MARKET, BY METHOD,  2021–2028 (USD MILLION)
                        TABLE 190 REST OF THE WORLD: MARKET, BY APPLICATION,  2021–2028 (USD MILLION)
                        TABLE 191 REST OF THE WORLD: MARKET, BY SAMPLE TYPE,  2021–2028 (USD MILLION)
                        TABLE 192 REST OF THE WORLD: MARKET, BY END USER,  2021–2028 (USD MILLION)
 
12 COMPETITIVE LANDSCAPE (Page No. - 210)
     12.1 OVERVIEW 
     12.2 STRATEGIES ADOPTED BY KEY PLAYERS 
             TABLE 193 OVERVIEW OF STRATEGIES ADOPTED BY KEY CYSTATIN C ASSAY MARKET PLAYERS
     12.3 MARKET RANKING ANALYSIS, 2022 
             FIGURE 29 CYSTATIN C ASSAY INDUSTRY RANKING ANALYSIS, 2022
     12.4 REVENUE SHARE ANALYSIS, 2022 
             FIGURE 30 REVENUE ANALYSIS OF TOP FOUR PUBLIC MARKET PLAYERS
     12.5 COMPANY EVALUATION MATRIX 
             12.5.1 STARS
             12.5.2 PERVASIVE PLAYERS
             12.5.3 PARTICIPANTS
             12.5.4 EMERGING LEADERS
                        FIGURE 31 CYSTATIN C ASSAY INDUSTRY: COMPANY EVALUATION MATRIX (2022)
     12.6 SMES/STARTUPS EVALUATION MATRIX 
             12.6.1 PROGRESSIVE COMPANIES
             12.6.2 STARTING BLOCKS
             12.6.3 RESPONSIVE COMPANIES
             12.6.4 DYNAMIC COMPANIES
                        FIGURE 32 CYSTATIN C ASSAY INDUSTRY: COMPANY EVALUATION MATRIX FOR STARTUPS/SMES (2022)
     12.7 COMPETITIVE BENCHMARKING 
             12.7.1 COMPANY FOOTPRINT ANALYSIS
                        TABLE 194 COMPANY FOOTPRINT ANALYSIS
                        TABLE 195 COMPANY PRODUCT FOOTPRINT
                        TABLE 196 COMPANY REGIONAL FOOTPRINT
                        TABLE 197 CYSTATIN C ASSAY MARKET: DETAILED LIST OF KEY SMES/STARTUPS
     12.8 COMPETITIVE SCENARIO 
             12.8.1 PRODUCT LAUNCHES AND APPROVALS
                        TABLE 198 PRODUCT LAUNCHES AND APPROVALS, 2022
             12.8.2 DEALS
                        TABLE 199 DEALS, 2021
 
13 COMPANY PROFILES (Page No. - 222)
     13.1 KEY PLAYERS 
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
             13.1.1 ROCHE DIAGNOSTICS LIMITED
                        TABLE 200 ROCHE DIAGNOSTICS LIMITED: BUSINESS OVERVIEW
                        FIGURE 33 ROCHE DIAGNOSTICS LIMITED.: COMPANY SNAPSHOT
             13.1.2 ABBOTT
                        TABLE 201 ABBOTT: BUSINESS OVERVIEW
                        FIGURE 34 ABBOTT: COMPANY SNAPSHOT
             13.1.3 THERMO FISHER SCIENTIFIC INC.
                        TABLE 202 THERMO FISHER SCIENTIFIC INC.: BUSINESS OVERVIEW
                        FIGURE 35 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT
             13.1.4 SIEMENS HEALTHCARE GMBH
                        TABLE 203 SIEMENS HEALTHCARE GMBH: BUSINESS OVERVIEW
                        FIGURE 36 SIEMENS HEALTHCARE GMBH: COMPANY SNAPSHOT
             13.1.5 BIO-TECHNE
                        TABLE 204 BIO-TECHNE: BUSINESS OVERVIEW
                        FIGURE 37 BIO-TECHNE: COMPANY SNAPSHOT
             13.1.6 AGILENT TECHNOLOGIES, INC.
                        TABLE 205 AGILENT TECHNOLOGIES, INC.: BUSINESS OVERVIEW
                        FIGURE 38 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT
             13.1.7 GENTIAN DIAGNOSTICS ASA
                        TABLE 206 GENTIAN DIAGNOSTICS ASA: BUSINESS OVERVIEW
                        FIGURE 39 GENTIAN DIAGNOSTICS ASA: COMPANY SNAPSHOT
             13.1.8 ABCAM PLC
                        TABLE 207 ABCAM PLC.: BUSINESS OVERVIEW
                        FIGURE 40 ABCAM PLC.: COMPANY SNAPSHOT
             13.1.9 GETEIN BIOTECH, INC.
                        TABLE 208 GETEIN BIOTECH, INC.: BUSINESS OVERVIEW
                        FIGURE 41 GETEIN BIOTECH, INC.: COMPANY SNAPSHOT
             13.1.10 SINO BIOLOGICAL, INC.
                        TABLE 209 SINO BIOLOGICAL, INC.: BUSINESS OVERVIEW
                        FIGURE 42 SINO BIOLOGICAL, INC.: COMPANY SNAPSHOT
             13.1.11 EUROLYSER DIAGNOSTICA GMBH
                        TABLE 210 EUROLYSER DIAGNOSTICA GMBH: BUSINESS OVERVIEW
             13.1.12 DIAZYME LABORATORIES, INC
                        TABLE 211 DIAZYME LABORATORIES, INC.: BUSINESS OVERVIEW
             13.1.13 KAMIYA BIOMEDICAL COMPANY
                        TABLE 212 KAMIYA BIOMEDICAL COMPANY: BUSINESS OVERVIEW
             13.1.14 RANDOX LABORATORIES LTD.
                        TABLE 213 RANDOX LABORATORIES LTD..: BUSINESS OVERVIEW
             13.1.15 DIASYS DIAGNOSTIC SYSTEMS GMBH
                        TABLE 214 DIASYS DIAGNOSTIC SYSTEMS GMBH: BUSINESS OVERVIEW
             13.1.16 CEPHAM LIFE SCIENCES
                        TABLE 215 CEPHAM LIFE SCIENCES: BUSINESS OVERVIEW
     13.2 OTHER PLAYERS 
             13.2.1 ETHOS BIOSCIENCES
             13.2.2 IMMUNODIAGNOSTICS LIMITED
             13.2.3 SEKISUI DIAGNOSTICS
             13.2.4 AALTO SCIENTIFIC, LTD.
             13.2.5 RAYBIOTECH LIFE, INC.
             13.2.6 ARBOR ASSAYS
             13.2.7 CUSABIO TECHNOLOGY LLC
             13.2.8 PROTEINTECH GROUP, INC.
             13.2.9 ZHEJIANG KANGTE BIOTECHNOLOGY CO., LTD.
 
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
 
14 APPENDIX (Page No. - 261)
     14.1 INSIGHTS FROM INDUSTRY EXPERTS 
     14.2 DISCUSSION GUIDE 
     14.3 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 
     14.4 CUSTOMIZATION OPTIONS 
     14.5 RELATED REPORTS 
     14.6 AUTHOR DETAILS 

The study involved four major activities in estimating the current size of the cystatin C assay market. Exhaustive secondary research was done to collect information on the market and its different subsegments. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. After that, market breakdown and data triangulation procedures were used to estimate the market size of the segments and subsegments.

Secondary Research

In the secondary research process, various secondary sources such as annual reports, press releases & investor presentations of companies, white papers, certified publications, articles by recognized authors, gold-standard & silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Business, and Factiva) were referred to identify and collect information for this study.

Primary Research

Extensive primary research was conducted after acquiring knowledge about the global market scenario through secondary research. Primary interviews were conducted from both the demand (Pathologist, Head of laboratory, Microbiologist) and supply sides (cystatin C assay manufacturers and distributors).

The following is a breakdown of the primary respondents:

Breakdown of Primary Participants:

Cystatin C  Assay Market Size, and Share

Note 1: Others include sales managers, marketing managers, and product managers.

Note 2. Tiers of companies are defined based on their total revenue. As of 2022: Tier 1 = >USD 5 billion, Tier 2 = USD 500 million to USD 5 billion, and Tier 3 = <USD 500 million.

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

Both top-down and bottom-up approaches were used to estimate and validate the total size of the cystatin C assay market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

  • The key players in the industry and markets have been identified through extensive secondary research.
  • The industry’s supply chain and market size, in terms of value, have been determined through primary and secondary research processes.
  • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources.

Cystatin C  Assay Market Size, and Share

To know about the assumptions considered for the study, Request for Free Sample Report

Cystatin C  Assay Market Size, and Share

Data Triangulation

After arriving at the overall market size—using the market size estimation processes—the market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics of each market segment and subsegment, the data triangulation, and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides in the cystatin C assay industry.

Report Objectives

  • To define, describe, and forecast the global cystatin C assay market based on product, method, applications, sample type, end users, and region.
  • To provide detailed information regarding the major factors influencing the growth of the market (drivers, opportunities, challenges, Restraints)
  • To strategically analyze micromarkets1 with respect to individual growth trends, prospects, and contributions to the total market
  • To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders.
  • To forecast the size of market segments with respect to four main regions—North America, Europe, Asia Pacific, Rest of the World.
  • To strategically profile key players and comprehensively analyze their product portfolios, market shares, and core competencies3.
  • To track and analyze competitive developments such as acquisitions, agreements, new product launches, and partnerships in the cystatin C assay market. market m

Available Customizations:

With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the report:

  • Product Analysis: Product matrix, which gives a detailed comparison of the product portfolios of each company.
  • Geographic Analysis:  Further breakdown of the European cystatin C assay market into specific countries.

Data Triangulation

After arriving at the overall market size—using the market size estimation processes—the market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics of each market segment and subsegment, the data triangulation, and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides in the cystatin C assay industry.

Report Objectives

  • To define, describe, and forecast the global cystatin C assay market based on product, method, applications, sample type, end users, and region.
  • To provide detailed information regarding the major factors influencing the growth of the market (drivers, opportunities, challenges, Restraints)
  • To strategically analyze micromarkets1 with respect to individual growth trends, prospects, and contributions to the total market
  • To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders.
  • To forecast the size of market segments with respect to four main regions—North America, Europe, Asia Pacific, Rest of the World.
  • To strategically profile key players and comprehensively analyze their product portfolios, market shares, and core competencies3.
  • To track and analyze competitive developments such as acquisitions, agreements, new product launches, and partnerships in the cystatin C assay market. market m

Available Customizations:

With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the report:

  • Product Analysis: Product matrix, which gives a detailed comparison of the product portfolios of each company.
  • Geographic Analysis:  Further breakdown of the European cystatin C assay market into specific countries.
Custom Market Research Services

We will customize the research for you, in case the report listed above does not meet with your exact requirements. Our custom research will comprehensively cover the business information you require to help you arrive at strategic and profitable business decisions.

Request Customization
Report Code
MD 8813
Published ON
Oct, 2023
Choose License Type
BUY NOW
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the Cystatin C Assay Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
CUSTOMIZED WORKSHOP REQUEST
+1-888-600-6441
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
©2023 MarketsandMarkets Research Private Ltd. All rights reserved
DMCA.com Protection Status Website Feedback